Detalles de la búsqueda
1.
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
Blood
; 142(10): 865-877, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37300386
2.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37717583
3.
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
Br J Cancer
; 125(7): 939-947, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34400804
4.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Br J Haematol
; 193(4): 750-760, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33650100
5.
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Lancet
; 396(10266): 1885-1894, 2020 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308471
6.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33189178
7.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755235
8.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34062004
9.
What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial.
J Thromb Thrombolysis
; 48(2): 315-322, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31168688
10.
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Br J Haematol
; 176(6): 908-917, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28211054
11.
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Am J Hematol
; 97(3): E83-E86, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34882831
12.
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Am J Hematol
; 96(10): E383-E386, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34161627
13.
Secondary HLH is uncommon in severe COVID-19.
Br J Haematol
; 190(5): e283-e285, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32526046
14.
Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.
Br J Haematol
; 190(5): e279-e282, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32526039
15.
The combination of an inclusive novel agent treatment strategy, pre-emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients.
Br J Haematol
; 186(3): e11-e13, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30864155
16.
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Br J Haematol
; 185(3): 588-592, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30255568
17.
Advances in off-the-shelf CAR T-cell therapy.
Clin Adv Hematol Oncol
; 17(3): 155-157, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30969953
18.
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
Hemasphere
; 8(1): e29, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38434533
19.
Is the revised International staging system for myeloma valid in a real world population?
Br J Haematol
; 180(3): 451-454, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27734463
20.
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Br J Haematol
; 160(5): 640-8, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23293871